The world’s only database of cell and gene therapy CDMOs worldwide that is continuously updated. For the next 24 hours, you can claim if for 30% off. Act fast, because this offer expires soon.
A contract manufacturing organization (CMO) is a company that provides manufacturing services to cell and gene therapy companies on a contract basis. Contract development and manufacturing organizations (CDMOs) are similar, in that they offer services that include cell therapy product development, manufacturing, clinical trial support, and commercial supply.
Contract Manufacturing for Cell and Gene Therapies
Among cell and gene therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise. Benefits of partnering with a cell or gene therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. This database features companies who specialize in manufacturing and clinical trial support specifically for cell and gene therapies (CGT).
In addition to industry giants that include Lonza, Catalent, WuXi Advanced Therapies, Minaris Regenerative Medicine, and others, there are specialty CDMOs serving the CGT marketplace. For example, FUJIFILM Cellular Dynamics opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products. Similarly, Helixmith, a biotech company with an extensive gene therapy pipeline and a CAR-T program targeting solid tumors, has expanded into CDMO services for early-stage CAR-T developers.
Anemocyte announced itself as the first BMO (Biotech Manufacturing Organization) in the field of cell and gene therapies. In addition to building 2000 sq. metres of GMP and GMP-compliant facilities for the production of ATMP’s, its FLYn’ICE project is using drones equipped with cryogenic pods to achieve temperature controlled transit of cell and gene therapies.
Other companies were formed for the sole purpose of being a cell therapy-focused CDMO, such as like Lykan Bioscience, which opened its doors in 2019. Likewise, ThermoGenesis’ CDMO services feature expertise in CAR-T cells, T cell receptor (TCR), tumor-infiltrating leukocytes (TILs), natural killer cells (NKs), iPSCs, and MSCs.
Of course, there have been hefty M&A deals inked within the cell and gene therapy CDMO sector as well. For example, industry behemoth Thermo Fisher Scientific snagged Brammer Bio for an astonishing $1.7 billion, while Catalent acquired Paragon Bioservices for an impressive $1.2 billion and MaSTherCell for $315 million.
Similarly, Hitachi Chemical Advanced Therapeutics Solutions (HCATS), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. Regenerative Medicine now operate under the joint name of Mineras Regenerative Medicine, while Charles River Laboratories (CRL) acquired Cognate BioServices for a hefty price tag of $875 million.
Database of Cell and Gene Therapy CMOs and CDMOs
Featuring nearly a hundred-companies worldwide, this is the world’s only database of cell and gene therapy CDMOs that is publicly available. If you are a cell therapy developer, you can use it to identify potential manufacturing partners. If you are a contract manufacturer, you can use it to identify the depth and breadth of your market competition.
The database features:
- Name of company
- Description of cell and gene therapy manufacturing services
- Link to company’s CMO / CDMO services
Use it to:
1) Compare companies capable of manufacturing your cell or gene therapy product
2) Identify market competitors within the cell therapy CMO industry
3) Identify new market entrants offering CMO services
4) Spot countries with a high number of cell and gene therapy CMOs (“geographic hotspots”)
Of course, your investment is backed by a Greater than 100% Money Back Guarantee.